Advances in the Management of Anal Cancer.
Although anal squamous cell carcinoma (ASCC) is an uncommon malignancy, its incidence has been increasing markedly in recent decades due to its association with human papilloma virus (HPV) infection. The well-established standard of care for localized ASCC consists of the combination of 5-fluorouracil (5FU) and mitomycin (MMC) chemotherapy, concurrent with external beam radiation therapy (EBRT). However, newer techniques are being actively pursued, including the use of newer radiation therapy (RT) technologies, such as intensity-modulated radiation therapy (IMRT). The areas of debate and development include the dosing and timing of MMC delivery, the role of cisplatin chemotherapy as an alternative to MMC, the replacement of the standard 96-h infusion of 5FU with oral capecitabine, the use of targeted chemotherapy agents, and the duration and dose of RT.
['Julie|Diana R|DR|', 'Goodman|Karyn A|KA|']
D000971:Antineoplastic Combined Chemotherapy Protocols D001005:Anus Neoplasms D000069287:Capecitabine D002945:Cisplatin D005260:Female D005472:Fluorouracil D006801:Humans D060828:Induction Chemotherapy D008403:Mass Screening D016685:Mitomycin D030361:Papillomavirus Infections D053918:Papillomavirus Vaccines D011829:Radiation Dosage D050397:Radiotherapy, Intensity-Modulated
Anal cancer Squamous cell carcinoma Human papilloma virus Definitive chemoradiation Intensity-modulated radiotherapy